SCHEMBL15568630

SCHEMBL15568630

O=C(CCl)c1cncnc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 2/20 0.52
GSK3B P49841 7/20 0.48
ALDH1A1 P00352 7/20 0.48
HIF1A Q16665 2/20 0.48
TRPA1 O75762 1/20 0.48
MAPK1 P28482 1/20 0.48
MAPT P10636 3/20 0.39
HPGD P15428 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
TP53 P04637 1/20 0.38
POLB P06746 2/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
THRA P10827 1/20 0.35
THRB P10828 1/20 0.35
PLOD2 O00469 1/20 0.34
BCAT2 O15382 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6249575 0.76 HCAR2 (0.52) HCAR2MAPTCYP3A4CYP2C19POLB
SCHEMBL7506719 0.76 HCAR2 (0.52) HCAR2GSK3BPOLBPLOD2BCAT2
SCHEMBL3721053 0.74 GSK3B (0.50) GSK3BALDH1A1HIF1ATRPA1MAPK1
SCHEMBL3829645 0.74 PLOD2 (0.65) HCAR2GSK3BALDH1A1HIF1ATRPA1
SCHEMBL20819323 0.74 HCAR2 (0.62) HCAR2GSK3BALDH1A1HIF1ATRPA1
SCHEMBL31069819 0.74 PLOD2 (0.65) HCAR2GSK3BALDH1A1HIF1ATRPA1
SCHEMBL6322774 0.73 HCAR2 (0.48) HCAR2ALDH1A1MAPTCYP3A4CYP2D6
SCHEMBL18906052 0.73 HCAR2 (0.54) HCAR2ALDH1A1HIF1AHPGDCYP1A2
SCHEMBL10588535 0.73 HDAC1 (0.50) GSK3BALDH1A1HIF1ATRPA1MAPK1
SCHEMBL5163325 0.73 HCAR2 (0.48) HCAR2ALDH1A1HIF1AMAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2885306-B1 IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE HOFFMANN LA ROCHE (CH) 2016-06-01 EP disclosed
EP-2885306-A1 IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE F. Hoffmann-La Roche AG (CH) 2015-06-24 EP disclosed
US-20150157739-A1 Imidazo[2,1]thiazol-3-one derivatives HOFFMANN-LA ROCHE INC. (US) 2015-06-11 US disclosed
WO-2014026881-A1 IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2014-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150157739-A1 Imidazo[2,1]thiazol-3-one derivatives MAPT, SNCA, PARK7 HCAR2 3974/4885GSK3B 170/4885ALDH1A1 1911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.